WHO Consults On Kick-Starting Pilot On Prequalification Of Biosimilars
Executive Summary
The World Health Organization is making inroads into its plan to prequalify biosimilars, starting with a pilot project involving two anti-cancer medicines. It has developed two assessment pathways to prequalify biosimilars, depending on whether not these products are already approved by a stringent regulatory authority. During the pilot phase, the fees associated with prequalification will be waived.
You may also be interested in...
ICH Expansion Prompts WHO To Review Definition Of 'Stringent Regulatory Authorities'
European research-based pharmaceutical industry association, EFPIA, says it "makes sense" for the World Health Organization to review the concept of "stringent regulatory authorities," which is linked to a country's membership of the International Council for Harmonisation.
WHO Moves Into Prequalification Of Biosimilars; Two Anticancers First In Line
The World Health Organization is to pilot the prequalification of biosimilars in a bid to make expensive cancer treatments more widely available to patients. Ritixumab and trastuzumab will be first in line. The EU generics and biosimilars industry has welcomed the initiative, saying the introduction of biosimilars in the field of oncology could lead to significant changes to standards of care for patients.
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.